[Recombinant VP1 protein of norovirus GII.4 (Caliciviridae: Norovirus) is capable to induse the production of cross-reacting antibodies].

Q3 Medicine

Voprosy virusologii Pub Date : 2025-07-21 DOI:10.36233/0507-4088-316

V A Lapin, D V Novikov, A Y Kashnikov, N V Epifanova, N A Novikova, E V Mokhonova, D A Melentev, M I Tsyganova, D E Zaitsev, V V Novikov

{"title":"[Recombinant VP1 protein of norovirus GII.4 (Caliciviridae: Norovirus) is capable to induse the production of cross-reacting antibodies].","authors":"V A Lapin, D V Novikov, A Y Kashnikov, N V Epifanova, N A Novikova, E V Mokhonova, D A Melentev, M I Tsyganova, D E Zaitsev, V V Novikov","doi":"10.36233/0507-4088-316","DOIUrl":null,"url":null,"abstract":"Introduction: Norovirus (NoV) is one of the main causes of acute gastroenteritis. Currently, there is no vaccine to prevent norovirus infection. Vaccines under development are based on the capsid protein VP1, which is capable of forming virus-like particles. The aim of the work was to analyze the immunogenic properties of the recombinant VP1 protein of NoV GII.4.Materials and methods: In the blood serum of animals immunized with the recombinant VP1 protein obtained by the authors, titers and avidity of total antibodies and IgM antibodies against NoV VP1 were determined using enzyme immunoassay. The ability of the obtained antibodies to interact with NoV of different genotypes was assessed using immunoelectron microscopy.Results: The recombinant VP1 protein induced high titer antibody production in animals. Total antibodies against VP1 had a high avidity, reaching 100%, which suggests that they have viral neutralizing activity. IgM antibodies had low avidity. Immunoelectron microscopy showed that IgG antibodies against VP1 protein of genotype GII.4 interact with wild-type NoV of genotype GII.7 and GII.17.Conclusion: The obtained recombinant protein induces a sufficiently strong immune response with the formation of high avidity polyclonal cross-reacting antibodies, which allows us to consider it as an antigen component of a NoV vaccine candidate.","PeriodicalId":23669,"journal":{"name":"Voprosy virusologii","volume":"70 3","pages":"282-290"},"PeriodicalIF":0.0000,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Voprosy virusologii","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36233/0507-4088-316","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Norovirus (NoV) is one of the main causes of acute gastroenteritis. Currently, there is no vaccine to prevent norovirus infection. Vaccines under development are based on the capsid protein VP1, which is capable of forming virus-like particles. The aim of the work was to analyze the immunogenic properties of the recombinant VP1 protein of NoV GII.4.

Materials and methods: In the blood serum of animals immunized with the recombinant VP1 protein obtained by the authors, titers and avidity of total antibodies and IgM antibodies against NoV VP1 were determined using enzyme immunoassay. The ability of the obtained antibodies to interact with NoV of different genotypes was assessed using immunoelectron microscopy.

Results: The recombinant VP1 protein induced high titer antibody production in animals. Total antibodies against VP1 had a high avidity, reaching 100%, which suggests that they have viral neutralizing activity. IgM antibodies had low avidity. Immunoelectron microscopy showed that IgG antibodies against VP1 protein of genotype GII.4 interact with wild-type NoV of genotype GII.7 and GII.17.

Conclusion: The obtained recombinant protein induces a sufficiently strong immune response with the formation of high avidity polyclonal cross-reacting antibodies, which allows us to consider it as an antigen component of a NoV vaccine candidate.

查看原文本刊更多论文

[诺如病毒GII.4（杯状病毒科：诺如病毒）重组VP1蛋白能够诱导产生交叉反应抗体]。

诺如病毒（NoV）是引起急性胃肠炎的主要原因之一。目前，没有预防诺如病毒感染的疫苗。正在开发的疫苗基于衣壳蛋白VP1，它能够形成病毒样颗粒。本研究的目的是分析重组VP1蛋白的免疫原性。材料与方法：用自制的重组VP1蛋白免疫动物血清，采用酶免疫法测定抗NoV VP1总抗体和IgM抗体的效价和亲和力。利用免疫电镜观察获得的抗体与不同基因型的NoV相互作用的能力。结果：重组VP1蛋白可诱导动物产生高滴度抗体。抗VP1的总抗体具有很高的亲和力，达到100%，这表明它们具有病毒中和活性。IgM抗体的贪婪度较低。免疫电镜显示，GII.4基因型VP1蛋白IgG抗体与GII.7和GII.17基因型野生型VP1蛋白相互作用。结论：所获得的重组蛋白可诱导较强的免疫应答，并形成高亲和度的多克隆交叉反应抗体，可作为NoV候选疫苗的抗原组分。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Voprosy virusologii Medicine-Infectious Diseases

CiteScore

2.00

自引率

0.00%

发文量

期刊介绍： The journal deals with advances in virology in Russia and abroad. It publishes papers dealing with investigations of viral diseases of man, animals and plants, the results of experimental research on different problems of general and special virology. The journal publishes materials are which promote introduction into practice of the achievements of the virological science in the eradication and incidence reduction of infectious diseases, as well as their diagnosis, treatment and prevention. The reader will find a description of new methods of investigation, new apparatus and devices.